[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) filed a Form 144 indicating a planned disposition of 89 common shares (≈ $1,255 market value) through Merrill Lynch on or after 4 Aug 2025. The shares represent <0.0001% of the company’s 119.2 million shares outstanding and were acquired via a restricted-stock vest on 1 Aug 2024.

The same insider, Latha Vairavan, previously sold an identical block of 89 shares for $1,329 on 5 May 2025. No other sales or material considerations are disclosed. Form 144 requires the filer to state that they possess no undisclosed adverse information and to acknowledge potential penalties for misstatements.

Investment-relevance: The proposed sale is de minimis and does not alter ownership structure, liquidity, or strategic outlook. It is therefore unlikely to affect ARQT’s valuation or trading dynamics.

Insights

Securities Analyst

TL;DR: Tiny insider sale (89 shares, $1.3k) is routine, non-dilutive, and immaterial to ARQT investors.

Rule 144 filings flag insider intent to sell restricted or affiliate-held stock. Here, the holder plans to divest 89 shares—an amount far below reporting or liquidity thresholds. With 119 million shares outstanding, the float impact rounds to zero. No price-sensitive details about operations, guidance, or strategic shifts emerge. Prior similar sale suggests a pattern of cashing out small vested lots. Accordingly, market impact and signaling value are negligible; this is compliance housekeeping rather than a substantive event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43240	89	1255.12	119201724	08/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2024	Restricted stock vest	Arcutis Biotherapeutics			89	08/01/2024	na

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Latha Vairavan 3027 Tawnsgate rd Ste 300 West lake village CA 91361	common	05/05/2025	89	1329.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many ARQT shares are being sold under this Form 144?

The filing covers 89 common shares of Arcutis Biotherapeutics.

What is the approximate market value of the shares to be sold?

The aggregate market value is $1,255.12 based on the filing.

When can the insider begin selling the shares?

The proposed sale date listed is August 4, 2025.

How does this sale compare to ARQT’s total shares outstanding?

The 89 shares equal less than 0.0001% of the 119,201,724 shares outstanding.

Were there any recent sales by the same insider?

Yes, the filer sold 89 shares on May 5, 2025 for gross proceeds of $1,329.